Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy

Paaladinesh Thavendiranathan; Tomoko Negishi; Emily Somerset; Kazuaki Negishi; Martin Penicka; Julie Lemieux; Svend Aakhus; Sakiko Miyazaki; Mitra Shirazi; Maurizio Galderisi; Thomas H Marwick

Journal article

Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy

Paaladinesh Thavendiranathan, Tomoko Negishi, Emily Somerset, Kazuaki Negishi, Martin Penicka, Julie Lemieux, Svend Aakhus, Sakiko Miyazaki, Mitra Shirazi, Maurizio Galderisi, Thomas H Marwick

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | ELSEVIER SCIENCE INC | Published : 2021

DOI: 10.1016/j.jacc.2020.11.020

Abstract

BACKGROUND: In patients at risk of cancer therapy-related cardiac dysfunction (CTRCD), initiation of cardioprotective therapy (CPT) is constrained by the low sensitivity of ejection fraction (EF) for minor changes in left ventricular (LV) function. Global longitudinal strain (GLS) is a robust and sensitive marker of LV dysfunction, but existing observational data have been insufficient to support a routine GLS-guided strategy for CPT. OBJECTIVES: This study sought to identify whether GLS-guided CPT prevents reduction in LVEF and development of CTRCD in high-risk patients undergoing potentially cardiotoxic chemotherapy, compared with usual care. METHODS: In this international, multicenter, pr..

View full abstract

University of Melbourne Researchers

Thomas Marwick Author Baker Department of Cardiometabolic Health

Grants

Awarded by National Health and Medical Research Council, Canberra, Australia

Awarded by Canadian Institutes of Health Research New Investigator Award

Awarded by National Heart Foundation of Australia

Funding Acknowledgements

This study was supported in part by a project grant (1119955) from the National Health and Medical Research Council, Canberra, Australia, and an unrestricted grant from General Electric Healthcare, Horten, Norway. At the Centre Hospitalier Universitaire (CHU) de Quebec site, the study was funded by the Fondation du CHU de Quebec. Dr. Thavendiranathan is supported by the Canadian Institutes of Health Research New Investigator Award (147814), the Ontario Early Research Award, and a Canada Research Chair in Cardio-oncology. Dr. Negishi is supported by a Fellowship (award reference no. 101868) from the National Heart Foundation of Australia. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.